INVESTORS & MEDIA

Tarrytown, New York (September 10, 2015) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that Maya Bermingham has joined as the first member of the company's Washington, D.C., office in the newly-created role of Executive Director, Public Policy. Bermingham is reporting to Joseph J. LaRosa, Senior Vice President, General Counsel and Secretary. She will lead policy activities and interaction with key government stakeholders, trade associations and advocacy groups, in addition to other responsibilities.

Bermingham brings a diverse array of policy and government relations experience to Regeneron. She previously served as Vice President and Senior Counsel at PhRMA, where for the past 12 years she developed and helped lead many of the association's key legal and policy initiatives. Prior to that role, she was an associate with the Washington office of the law firm Morgan Lewis. Bermingham also served on the health policy staff of the Senate Finance Committee, working for then-Chairman Daniel Patrick Moynihan (D-NY), and on the staff of the U.S. Agency for International Development.

"Maya brings tremendous, highly relevant experience to the Regeneron team, having worked extensively in healthcare policy, on the Hill, and as an advisor to the largest pharmaceutical and biotechnology companies in the country," said LaRosa. "Maya is the first of a growing Washington-based team that will ensure our company and patient interests are well represented as Regeneron continues our rapid growth."

"I am attracted to Regeneron's culture of scientific and business excellence, and I am excited to lead the company in the policy arena as we continue our work to innovate for patients, bringing them new medicines for serious diseases," said Bermingham.

Bermingham received her B.A. from Harvard and her J.D. from the New York University School of Law, where she was a Staff Editor for the Review of Law and Social Change.

About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Your IR Contact at Regeneron:
Manisha Narasimhan, Ph.D., Tel. 914.847.5126
E-Mail: manisha.narasimhan@regeneron.com

Your Media Contact at Regeneron:
Alexandra Bowie, Tel. 914.847.3407
E-Mail: alexandra.bowie@regeneron.com